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Abstract: Malignant gliomas, despite aggressive multimodal therapies and adequate supportive care, still
maintain poor prognosis. Solid lipid nanoparticles (SLN) are colloidal carriers that could be regarded as a
highly flexible platform for brain tumor imaging and therapeutical purposes. In this chapter we will first
describe brain tumors characteristics and conventional therapeutical approaches. In the subsequent
sections, we will analyze SLN properties, effectiveness, and future perspectives in both imaging and
targeted treatment of malignant gliomas.
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Brain tumors
Brain tumors constitute a complex of heterogeneous
clinico-pathological diseases, often characterized by
poor prognosis and associated with low quality of
life (Buckner et al., 2007; DeAngelis, 2001; Louis,
Pomeroy, & Cairncross, 2002).
Central nervous system (CNS) tumors are clas-
sified by the World Health Organization
according to their presumed cell of origin as well
as to their localization, histopathological appear-
ance, and lineage markers (Louis et al., 2007).
Primary brain tumors show in the United States
an average annual incidence rate of 14.4
per 100,000 persons (Fisher, Schwartzbaum,
Wrensch, & Wiemels, 2007) and about half of
them are histologically malignant, showing an
annual gender incidence rate of 7.0/100,000 in
men and 5.2/100,000 in women (Fisher et al., 2007).
Primary malignant brain tumors account for the
first cause of death for solid tumors in children
and the third cause of death for all cancer types in
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adolescents and young adults (Buckner et al.,
2007). Primary malignant CNS neoplasms show
a relative survival probability at 2 years of 37.7%
and at 5 years of 30.2% (Fisher et al., 2007).
These epidemiological data clearly suggest that
primary malignant brain tumors — despite a
lower incidence rate compared to all cancers
(about 2%) — display high morbidity and mortal-
ity rate and consequently they could be numbered
among the most devastating human neoplastic
diseases (Buckner et al., 2007).
Gliomas are the most common type among
primary CNS tumors and account for an average
annual incidence rate in the United States of
6.42/100,000 persons (Fisher et al., 2007).
Gliomas include different histopathological enti-
ties: astrocytomas, oligodendrogliomas, mixed
gliomas (a combination of oligodendroglial and
astrocytic features), and ependimomas (Fisher
et al., 2007; Norden & Wen, 2006). According
to the degree of differentiation and anaplasia,
gliomas could receive a histopathological grade
that, in turn, strictly correlates with prognosis.
High-grade gliomas (otherwise defined malig-
nant gliomas), accounting for more than half of
all gliomas in adults and for 78% of all primary
malignant CNS tumors, include glioblastomas,
anaplastic astrocytomas, anaplastic oligodendro-
gliomas, and anaplastic oligoastrocytomas.
Survival time after diagnosis of malignant glioma
depends on both the histological subtype and the
age at onset (Fisher et al., 2007; Sathornsumetee,
Rich, & Reardon, 2007). The 2-year relative
survival probability value (according to the his-
tology and age group at diagnosis) in the United
States is variable: 1.4–29.8% for glioblastomas,
4.1–71.4% for anaplastic astrocytomas,
4.9–76.5% for anaplastic oligodendrogliomas,
and 37.6–84.7% for mixed gliomas (Fisher
et al., 2007).
Genetic factors and molecular markers were
recently identified as prognostic indicators for
malignant gliomas, in addition to previously
known clinical, histological, and neuroradiological
factors such as age and functional status at diag-
nosis, extent of surgical resection, degree of necro-
sis, and pre- and postsurgery tumor size.
(Sathornsumetee et al., 2007).
Different glioma subtypes and grades exhibit a
set of peculiar genetic alterations, mainly occur-
ring in genes encoding proteins involved in sig-
nal transduction pathways and cell-cycle
regulation of tumor initiation and progression.
These genetic changes frequently involve growth
factors that can be overexpressed (i.e., epidermal
growth factor — EGF, platelet-derived growth
factor — PDGF, fibroblast growth factor, ciliary
neurotrophic factor), or show activating mutations
like those commonly occurring (40% of glioblas-
tomas) in the EGF receptor— EGFR gene. Other
common molecular changes include tumor sup-
pressor loss (i.e., Phosphatase and Tensin
(PTEN) mutations, occurring in nearly 25% of
glioblastomas) or deletions, ink4a/arf locus dele-
tions, Rb and p53 mutations (Cavaliere, Wen, &
Schiff, 2007; Fisher et al., 2007; Fomchenko &
Holland, 2006; Martin-Villalba, Okuducu, & von
Deimling, 2008; Sanson, 2008).
For instance, altered EGFR expression
inversely correlates to survival increasing prolif-
eration rates, resistance to chemotherapy, inva-
sion, and apoptosis (Rich & Bigner, 2004).
Moreover, PDGF ligands are highly expressed in
malignant gliomas and the activation of PDGF
receptors stimulates proliferation, resistance to
apoptosis, cellular motility, and angiogenesis
(Rich & Bigner, 2004).
In addition to the aforementioned variability in
the pattern of genetic alterations, during tumor
progression glioma cells could display additional
mutations and epigenetic changes that yield these
tumors to become genetically and phenotypically
different from the cancer-initiating focus and per-
haps sharing variable levels of chemo- and/or
radiosensitivity (Cavaliere et al., 2007; Fom-
chenko & Holland, 2006; Wong, Bendayan,
Rauth, Li, & Wu, 2007). Among these latter
additional changes we could mention the hyper-
methylation of methylguanine-DNA-methyltrans-
ferase (MGMT) promotor (that results in reduced
MGMT expression and consequently in a better
response to alkylating drugs) and contrariwise the
possible development of a multidrug resistance
phenotype by the activation of membrane-asso-
ciated transporters (such as P-glycoprotein) that
actively expel from the cytoplasm a broad range
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of cytotoxic agents (Criniere et al., 2007; Martin-
Villalba et al., 2008; Wong et al., 2007). In con-
clusion, gene expression profile could help to
differentiate glioma subtypes in order to identify
tumor indistinguishable on morphological
ground (such as primary and secondary glioblas-
tomas) and thereby to predict clinical course
(Martin-Villalba et al., 2008).
Taken together, previously reported data sug-
gest that malignant gliomas could be regarded as a
group of different diseases, each of them showing
distinctive clinical–pathological behavior (Fisher
et al., 2007; Louis et al., 2002). Consequently, the
recognition of specific prognostic factors may be
crucial to identify different subgroup of patients
who could be more sensitive to differing schedules
of conventional treatment options (i.e., combining
chemotherapeutics and/or radiotherapy with
treatment sensitizers) (Cavaliere et al., 2007).
Furthermore, the identification of these prognos-
tic factors will open a new therapeutical way (the
so-called molecular chemotherapy) both by using
new treatment agents (including, i.e., monoclonal
antibodies, cytokines, synthetic molecules, gene
constructs) and by targeting different extra- and/
or subcellular pathways (such as cell-cycle control,
cell migration, tissue invasion, and angiogenesis)
(Cavaliere et al., 2007; Sanson, 2008).
To date, despite aggressive multimodal thera-
peutic approaches (such as surgery, radiation
therapy, and chemotherapy) and adequate sup-
portive care, malignant gliomas still maintain
poor prognosis. Among newly diagnosed glioblas-
toma patients that receive the best treatment
schedule possible median survival rate is 14.6
months (Buckner et al., 2007; Carpentier, 2005;
Fisher et al., 2007; Norden & Wen, 2006; Norden,
Drappatz, & Wen, 2008a; Rich & Bigner, 2004;
Stupp et al., 2005).
This substantial failure of conventional treat-
ments could be ascribed to three main reasons,
principally related to the peculiar characteristics
of high-grade gliomas.
1. First of all, the inability to achieve effective
intratumoral concentrations of common
chemotherapeutic agents, mainly due to the
presence of the blood–brain (BBB) and the
brain–tumor barrier, as well as to the intrinsic
properties of commonly used cytotoxic drugs
(i.e., poor specificity, high systemic toxicity,
and propensity to induce chemoresistance).
2. Furthermore, the characteristic early
infiltrative behavior of these neoplasms that
limits surgical aggressive resections and
thereby negatively influence multimodal
approaches.
3. Finally, the noticeable cellular and genetic
intratumoral, spatial–temporal heterogeneity
that modifies the individual response to
chemo- and radiotherapy (Cavaliere et al.,
2007; Fomchenko & Holland, 2006; Sanson,
2008; Sanson, Laigle-Donadey, & Benouaich-
Amiel, 2006).
The normal BBB is a highly effective physical
and physiological barrier that regulates the
CNS homeostasis and thereby controls the deliv-
ery of drugs to the brain (Blakeley, 2008; Kaur,
Bhandari, Bhandari, & Kakkar, 2008).
Mechanical limitations are mainly carried out by
endothelial cell tight junctions that in turn are
supported by the absence of fenestration and the
reduction of pinocytotic vesicles at endothelial
level and by the presence of a composite anatomi-
cal barrier constituted by astrocytic end-feet, peri-
cytes, and extracellular matrix. Physiological
properties that characterize the normal BBB are
formed by the presence of both high electrical
resistance across the endothelial cell barrier
(even reaching 2,000 ! cm2) and effective efflux
transporters (mainly members of the adenosine
triphosphate-binding cassette — ABC), located
on cell surface of endothelial and cancer cells
(Blakeley, 2008; Kaur et al., 2008; Pardridge,
2007; Wong et al., 2007).
Several factors influence the specific ability of a
given molecule to pass through the BBB, includ-
ing size, water solubility, charge, plasma protein
binding, and serum concentration (Blakeley, 2008;
Kaur et al., 2008). Other factors, such as cerebral
blood flow rate, influx and efflux values at the
BBB and blood–CSF (cerebrospinal fluid) barrier,
rate of metabolism, and interactions–binding of
the drug in the brain, may influence drug cerebral
distribution (Kaur et al., 2008). However, only less
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than 5% of all drugs proved active into CNS,
and almost 100% of large molecule drugs —
including recombinant proteins and enzymes,
monoclonal antibodies, antisense agents, short
interfering RNA, and gene products — under
physiological conditions do not cross the BBB
(Pardridge, 2007). Invasiveness and neoangioge-
netic processes of malignant gliomas are accom-
panied by focal disruptions of the BBB and
increased permeability of capillary endothelium.
Nevertheless, this BBB disruption is not able to
produce any effect on tumor therapy response
probably because both intrinsic characteristics of
tumor cells (i.e., high proliferation rate and
chemo- and radiotherapy escape phenomena)
and the not homogeneous localization of these
vascular breakages into the tumor mass
(Beduneau, Saulnier, & Benoit, 2007).
Nowadays, the most common chemothera-
peutic agents in clinical use for malignant
glioma treatment include DNA-alkylating cyto-
toxic drugs (such as carmustine), triple combi-
nation (often used at high dosages) of
procabazine, cisplatin, and vincristine, and the
more recently available temozolomide (TMZ),
etoposide, and lomustine. Novel strategies to
achieve effective intratumoral bioavailability of
chemotherapeutic agents, regardless of their
physical–chemical properties, partially escaping
in a passive manner the BBB control, were
proposed. Drug dose intensification, use of
more lipophilic analogs, and intra-arterial deliv-
ery preceded by iatrogenic disruption of the
BBB using osmotics, magnetic resonance ima-
ging (MRI)-guided ultrasound, or radiotherapy
showed debatable or uncertain results (Blake-
ley, 2008; Rich & Bigner, 2004). Postsurgical
implantation into residual tumoral cavity of
drug-embedded biodegradable polymers or
catheters (for both convection-enhanced deliv-
ery or reservoir continuous release) are in clin-
ical use but are still limited to a well clinically
selected group of patients referring to much
more selected neurosurgical teams (Beduneau
et al., 2007; Blakeley, 2008; Kaur et al., 2008).
Furthermore, active methods to cross the BBB
are in study and will be evaluated in the follow-
ing sections of this chapter.
Drug delivery systems — solid lipid nanoparticles
In order to obtain a better profile of drug stabi-
lity, biodistribution, pharmacokinetics, and antic-
ancer activity after parenteral administration, so
allowing more targeted antitumoral activity,
lower systemic toxicity and reduced adverse
side effects, several passive and active carriers
were developed. Among them, lipoplexes, den-
drimers, cyclodextrins, liposomes, microspheres,
niosomes, and nanoparticles were investigated in
experimental models and some of them were
even put on the market (Barratt, 2003; Cho,
Wang, Nie, Chen, & Shin, 2008; Gaidamakova,
Backer, & Backer, 2001; Kim et al., 2005;
Koziara, Lockman, Allen, & Mumper, 2006;
Kreuter, 2001; Lu et al., 2005; Mehnert &
Mader, 2001; Muller & Keck, 2004; Olbrich,
Bakowsky, Lehr, Muller, & Kneuer, 2001;
Pardridge, 2007; Parveen & Sahoo, 2008; Rich
& Bigner, 2004; Serikawa et al., 2006; Tiwari &
Amiji, 2006; Wong et al., 2007).
An effective delivery system should display
some of the following characteristics:
– ability to load a high amount of drugs,
– physical and chemical storage stability,
– low systemic toxicity (that is to say favorable in
vivo fate of the carrier)
– easy and large-scale production process,
– low overall cost,
– chance of specifically target tumor tissue (Kaur
et al., 2008; Mehnert & Mader, 2001).
Solid lipidnanoparticles (SLN) are colloidal (namely,
submicron sized) carriers constituted by a solid lipid
matrix at room and body temperature, composed of
physiological lipids (lipid acids, mono-, di-, or trigly-
cerides, glycerine mixtures, and waxes), and stabi-
lized by biocompatible surfactants (nonionic or
ionic) (Marcato & Duran, 2008; Wissing, Kayser, &
Muller, 2004;Wong et al., 2007). SLNwere shown to
satisfy nearly all the aforementioned characteristics
combining some advantages (mainly drug bioavail-
ability, controlled release, and drug targeting) and
avoiding disadvantages of other vehicles in a more
simple and versatile way (Blasi, Giovagnoli, Schoub-
ben, Ricci, & Rossi, 2007; Kaur et al., 2008).
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SLN could be prepared by different approaches
such as high-pressure homogenization at high or
low temperatures, warm microemulsions (Fig. 1),
solvent emulsification–evaporation–diffusion, and
high-speed stirring and/or sonication (Blasi et al.,
2007; Muller, Mader, & Gohla, 2000). The first
two processes show the most versatile technique
(mainly in terms of avoidance of nonbiocompati-
ble components, scale-up feasibility, and steriliza-
tion) and consequently are the most frequently
used (Blasi et al., 2007).
SLN could carry different agents including both
hydrophilic and lipophilic therapeutics and diag-
nostic tools. For parenteral administration benzo-
diazepines, antipsychotics, pilocarpine, steroids,
timolol, antineoplastic agents, peptides, and more
recently gene therapeutical agents, such as plas-
mid DNA and antisense oligonucleotides (AS-
ODN), and MRI contrast agents were successfully
incorporated into SLN (Dass, 2002; Gasco, 2007;
Manjunath & Venkateswarlu, 2005; Muller et al.,
2000; Peira et al., 2003; Wissing et al., 2004).
Furthermore, SLN could be administered by dif-
ferent routes (such as parenteral, transdermal,
oral, and ocular) (Gasco, 2007). The drug solubi-
lity in the lipid melt together with the structure
and the polymorphic state of the lipid matrix are
the main factors that influence the drug loading
capacity (Wissing et al., 2004).
SLN are able to increase chemical stability and
to protect from systemic degradation the vehicu-
lated molecule (hence consequently increasing its
plasma half life) by virtue of the presence of a
solid hydrophobic core (the so-called solid high
melting fat matrix) in which lipophilic compounds
are dissolved or dispersed (Kaur et al., 2008;
Wissing et al., 2004). The carried drug — accord-
ing to its lipid ratio and solubility — could be
mainly located into the core, into the shell or
dispersed into the matrix of the SLN (Wissing
et al., 2004). By modifying the composition of
the lipid matrix, the type and the concentration
of the surfactant, and the productions parameters
it is possible to modulate the drug release profile:
drug-enriched shell (burst release), solid solution
(intermediate release), and drug-enriched core
(sustained release, even for up to several weeks)
(Cavalli et al., 2003; Wissing et al., 2004).
The SLN content of only well-tolerated,
biocompatible, and biodegradable lipids and the
avoidance of any organic solvent during the
preparation process justify the common statement
that SLN could be regarded as safe (Blasi et al.,
2007; Fundaro et al., 2000; Zara et al., 1999,
2002a, 2002b).
Moreover, SLN could be easily sterilized and
produced on a large industrial scale, so reducing
the overall cost (Blasi et al., 2007; Gasco, 2007;
Kaur et al., 2008).
Several in vivo experimental studies demon-
strated that pharmacokinetics and body distribu-
tion profile of different drugs after parenteral
administration are significantly changed if vehicu-
lated by SLN. Among the tested agents we could
count different compounds for which the passage
through the BBB is usually troublesome: che-
motherapeutics (i.e., doxorubicin, paclitaxel, idar-
ubicin, camptothecin, etoposide, retinoic acid,
TMZ), chemosensitizers (such as verapamil and
cyclosporine-A), neuroleptics (such as clozapine),
and contrast agents for MRI. These studies (that
will be better analyzed in the following section)
clearly demonstrated that SLN are able to
significantly increase plasma peak, modify plasma
concentration curve (raising the area under
curve — AUC — from 3- to 20-fold and lowering
the rate of clearance so increasing plasma half-
lives), and reduce the volume of distribution
(Fundaro et al., 2000; Huang, Zhang, Bi, & Dou,
2008; Manjunath & Venkateswarlu, 2005; Shenoy,
Vijay, & Murthy, 2005; Wissing et al., 2004; Wong
et al., 2007; Yang et al., 1999; Zara et al., 1999,
2002a, 2002b). Furthermore, a different body
Phospholipids
Loaded drug
Inner lipid matrix
Fig. 1. Schematic structure of loaded SLN obtained by warm
microemulsion method.
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distribution pattern of the drug was shown: usually
the highest concentrations and mean residence
times (MRT) are found in the brain, the lowest
ones are seen in lung, heart, and kidney, and vari-
able results are obtained from liver and spleen
(Fundaro et al., 2000; Huang et al., 2008; Manju-
nath & Venkateswarlu, 2005; Shenoy et al., 2005;
Wissing et al., 2004; Yang et al., 1999; Zara et al.,
1999, 2002a, 2002b). These properties, probably
justified by the effect of SLN on both the rate of
crossing biologic barriers and the pattern of drug
release, coupled with the reduction of the drug
total dose needed, could significantly contribute
to decrease side effects of carried agents (Shenoy
et al., 2005).
Compared to other vehicles, SLN show a higher
ability to escape the reticuloendothelial system
(RES), so bypassing liver and spleen filtration
and consequently increasing the bioavailability of
the carried agent (Cho et al., 2008; Kaur et al.,
2008). SLN characteristics (mainly size and sur-
face) could be easily modified in order to modu-
late the body distribution hence increasing
bioavailability into CNS of the complex drug car-
rier. Size not exceeding a maximum diameter of
200 nm, sphericity, and adequate deformability
are crucial peculiarities to ensure the escape
from the sinusoidal spleens (Cho et al., 2008;
Kaur et al., 2008). The coating of SLN surface
with a hydrophilic or flexible polymer (such as
polyethylene glycol, PEG) and/or the use of a
surfactant (such as polysorbate and Epikuron)
prevent opsonization [namely, the recognition by
macrophage membrane of peculiar blood plasma
proteins (opsonin) adsorbed onto the colloidal
carrier] and the consequent phagocytosis carried
out by macrophages in the liver (Cho et al., 2008;
Kaur et al., 2008). This mechanism was summar-
ized in the concept of the “differential protein
adsorption” under that physical–chemical surface
characteristics of nanoparticles induce qualita-
tively and quantitatively different adsorption pat-
terns that in turn determine the in vivo fate of the
carrier system (Muller & Keck, 2004). In addition
to opsonins (mainly immunoglobulins and com-
plement factors), that facilitate RES recognition,
dysopsonins (such as albumin, apolipoprotein A-I,
A-IV, C-III, and H) are contrariwise able to
reduce the affinity of colloidal carriers to RES
and perhaps to increase passive targeting to spe-
cific organs only by modifying the composition of
the nanoparticle (W. Mehnert & Mader, 2001;
Muller & Keck, 2004).
The mechanisms by which SLN cross the BBB
are not completely understood but it is indisputa-
ble that a central role is played by the interactions
between plasma proteins adsorbed onto the SLN
surface and endothelial cells, hence facilitating or
hindering nanoparticles adhesion and subse-
quently activating or not endocytotic process
(Goppert & Muller, 2005; Kreuter, 2001; W. Meh-
nert & Mader, 2001). Among proteins adsorbed
onto the SLN surface, ApoE, Apo C-II, albumin,
and immunoglobulin G seem to be crucial in the
site-specific targeting to the brain (Blasi et al.,
2007; Goppert & Muller, 2005). Other mechan-
isms, namely, increased retentions of nanoparti-
cles in the brain blood capillaries and
transcytosis, could be advocated and could work
together with the aforementioned endocytotic
process (Blasi et al., 2007).
Furthermore, different surfactants (such as
Polysorbate 80 and Poloxamer 188) were shown
to facilitate the BBB crossing of different drugs
(i.e., doxorubicin) vehiculated by both polybutyl-
cyanoacrylate (PBCA) nanoparticles and SLN
(Blasi et al., 2007; Cho et al., 2008; Dehouck
et al., 1997; Goppert & Muller, 2005; Kaur et al.,
2008; Petri et al., 2007; Steiniger et al., 2004).
For instance, our group showed that in vivo
SLN containing stearic acid and PEG 2000 as
stealthing agents, unloaded or loaded with differ-
ent chemotherapeutics (i.e., doxorubicin), are able
to facilitate the passage through the BBB and to
increase the bioavailability of the drug into the
brain tissue compared to nonstealth SLN or free
drug solutions; moreover, stealth SLN show lesser
degree of recognition by the RES so prolonging
drug plasma half-life (Fundaro et al., 2000; Podio,
Zara, Carazzonet, Cavalli, & Gasco, 2000b; Zara
et al., 2002b).
Yang and Colleagues showed that camptothe-
cin-loaded SLN stabilized by Poloxamer 188 com-
pared to the free solution of this antineoplastic
agent after i.v. administration induce a higher
maximum concentration (corresponding to 180%
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increase) and a better profile of the AUC/dose
curve and MRT in the brain, heart, and RES
(Yang et al., 1999).
Koziara and Colleagues evaluated the CNS
uptake of two kinds of SLN composed by the
emulsifying wax (E wax) or Brij 72 as matrix,
and, respectively, Brij 78 and Tween 80 as surfac-
tant. The SLN were labeled with [3H]cetyl-alcohol
and the transport of the SLN was measured by an
“in situ” rat brain perfusion method. A significant
increase in the CNS uptake of both types of SLN
was observed compared to [14C]sucrose (Koziara,
Lockman, Allen, & Mumper, 2003, 2004). The
same group confirmed the aforementioned
results in an analogous experiment using pacli-
taxel-loaded polysorbate nanoparticles (Koziara
et al., 2004).
Petri and Colleagues recently showed in a in vivo
rat intracranial glioblastoma model that both the
surfactants Polysorbate 80 and Poloxamer 188 pro-
mote the adsorption onto PCBA–nanoparticles of
various blood plasma proteins, including different
classes of apolipoprotein (respectively Apo E and
Apo A-I). These apolipoproteins in turn activate a
specific receptor-mediated mechanism at the capil-
lary brain endothelial cells: Polysorbate 80–Apo E
complex activate a LDL-receptor mediated endo-
cytosis and Poloxamer 188–Apo A-I stimulate a
scavenger receptor class B type I (SR-BI)-
mediated nanoparticle adhesion (Dehouck et al.,
1997; Petri et al., 2007; Steiniger et al., 2004).
Moreover, the use of differently charged sur-
factants significantly influences the passage
through the BBB. Lockman and Colleagues
evaluated the effects of differently charged nano-
particles on both the BBB integrity and the brain
permeability. The authors showed that only neu-
tral and low concentrations of anionic nanopar-
ticles warrant the BBB integrity and that the
brain uptake is better for low concentration of
anionic nanoparticles. These results suggest that
neutral and low concentrations of anionic nano-
particles can be regarded as effective colloidal
carriers to the brain (Lockman, Koziara,
Mumper, & Allen, 2004).
In conclusion, the aforementioned data show
that SLN could be effectively and easily tailored
(mainly acting on the composition of their surface)
in order to passively increase CNS targeting (pas-
sive targeting). Furthermore, SLN are able to
allow a more specific targeting directed to genetic
and phenotypic features displayed by brain
tumors, the so-called active targeting, that will be
discussed in the following sections of this chapter
(Parveen & Sahoo, 2008).
Solid lipid nanoparticles and brain tumors
As introductory remarks we have to remind that
in vitro and in vivo experimental glioma models
are not able to fully reproduce the extremely com-
plex characteristics of human gliomas, both
phenotypically and genotypically. More in details,
in vitro models based on established primary ani-
mal or human glial tumor cell cultures (Barth,
1998; Claes et al., 2008; Fomchenko & Holland,
2006; Martinez-Murillo & Martinez, 2007;
Mathieu, Lecomte, Tsanaclis, Larouche, & Fortin,
2007) are useful to study biochemical and biologi-
cal tumor cell properties (such as chemo- and
radiosensitivity) but cannot recapitulate the inter-
actions between the tumor and the host environ-
ment (i.e., neoangiogenesis and immunological
reactions) as well as the genetic variability of
human gliomas. Furthermore, in vivo models
(mainly subcutaneous or brain orthotopic xeno-
grafts of selected primary glioma cell cultures),
although influenced by tumor–host interactions,
do not show some distinctive phenotypical
features of naïve malignant gliomas — such as
diffuse infiltrative behavior or angiogenesis.
Moreover, these models are lacking genetic het-
erogeneity and native stromal support as well as
provide a synchronous instead of a stepwise dis-
ease development paradigm (Claes et al., 2008;
Fomchenko & Holland, 2006). In conclusion,
experimental glioma models are not able to accu-
rately reproduce the naturally occurring disease
and consequently the findings obtained from
these models have to be critically and with careful
consideration translated into clinical phase I and
II trials and hence to clinical practice (Claes et al.,
2008; Fomchenko & Holland, 2006).
In the following sections we will mainly focus on
SLN prepared by our group from warm
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microemulsions. Microemulsions are chemical–
physical systems that are composed of oil,
water, cosurfactant, and surfactant, and that
show an interfacial tension near zero, thus
accounting for their long-term stability. Microe-
mulsion nanodroplets display a mean diameter
below 80 nm. Warm microemulsions are pre-
pared at temperature ranging from 60C to
80C by using melted lipids (such as fatty acids/
triglycerides) and are subsequently dispersed in
cold water. Nanodroplets obtained using this
procedure become SLN, which are successively
washed by tangential flow filtration. SLN display
spherical shape and a narrow size distribution.
The zeta potential is always high (30/40mV),
being negative or positive according to the start-
ing formulation.
Drugs of different structure and lipophilicity,
such as paclitaxel and doxorubicin, were loaded
into SLN using different methods. Drug-loaded
SLN show a mean diameter ranging from 80 to
200 nm, depending on the chemical characteristics
and the amount of the incorporated molecules.
In vitro experimental models
Intracellular trafficking of nanoparticles
In previous sections of this chapter we already
evaluated the properties that a systemically admi-
nistered colloidal carrier must display in order to
effectively reach brain tumor mass. At this level,
the carrier should also display other abilities in
order to pass through the selective plasma mem-
brane and to reach effective concentrations in the
cytoplasm of neoplastic cells as well as to display a
controlled drug release.
In nonphagocytic cells, the preferential mechan-
ism of nanocarriers cellular uptake is mediated by
endocytosis (Rejman, Oberle, Zuhorn, & Hoek-
stra, 2004; Soldati & Schliwa, 2006). Endocytic
pathway of nanoparticles starts at the plasma
membrane level and it can be either clathrin-
dependent or clathrin-independent, and the latter
could be in turn divided into caveolar or clathrin–
caveolae-independent (Mayor & Pagano, 2007).
The first step of the clathrin-mediated endocytosis
is a receptor-mediated process based on ligand–
receptor recognition and interaction at membrane
level. Subsequently, the pathway progress by gen-
erating clathrin-coated pits that invaginate into
the cytoplasm and then detach from it, so forming
the endocytic vesicles. Therefore, these vesicles
undergo to both early and late endosomal trans-
port and lastly to lysosomal digestion. On the
other hand, caveolin-coated vescicles invaginate
from plasma membrane domains which are espe-
cially enriched in cholesterol and sphingolipids
(Simons & Ikonen, 1997). This caveolae-mediated
uptake could be very advantageous in carrier-
mediated drug delivery because nanoparticles
can avoid the lysosomal degradation, so increasing
their cytoplasmic half-life and consequently main-
tain for longer periods a sustained intracellular
drug release (Shin & Abraham, 2001). However,
Lai and Colleagues suggested that certain types of
polymeric nanoparticles can exploit a nonclathrin,
noncaveolae, and cholesterol-independent path-
way in order to undergo nondegradative traffick-
ing into HeLa cells (Lai et al., 2007). Among other
physiological mechanisms perhaps involved in
nanocarrier intake spontaneous fluid-phase
macropinocytosis could be included. This process,
commonly occurring in all eukaryotic cells during
their life time, is characterized by cyclic internali-
zation of plasma membrane bits in which sub-
stances dissolved in the extracellular fluids are
entrapped. Through this physiological recycling
pathway it is possible that positively charged or
neutral nanoparticles glued to the negative outer
surface of the cell membrane could reach the
cytoplasm (Partlow, Lanza, & Wickline, 2008).
One or more of the aformentioned pathways
could be involved in neoplastic cellular uptake of
nanoparticulate carriers, depending on their size,
z-potential, chemical characteristics, and coated
molecules (Cho et al., 2008; Edetsberger, Gaubit-
zer, Valic, Waigmann, & Kohler, 2005; Vasir &
Labhasetwar, 2007; Vijayaraghavalu, Raghavan,
& Labhasetwar, 2007).
Several studies demonstrated that SLN (includ-
ing also both polymer–lipid hybrid nanoparticles
and nanostructured lipid carriers) are able to easily
enter into the cytoplasm of different tumoral cells
including U373 (human astrocytoma), U87 MG
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(human glioblastoma–astrocytoma), Lipari
(human glioblastoma), and C6 (rat glioma)
(Brioschi et al., 2009; Lim, Lee, & Kim, 2004;
Miglietta, Cavalli, Bocca, Gabriel, & Gasco,
2000; Serpe et al., 2006; Stevens, Sekido, & Lee,
2004; Wong, Bendayan, Rauth, Wu, 2004; Wong
et al., 2006a, 2006b). Nevertheless, the exact
mechanism by which SLN cross the cell mem-
brane is till now poorly understood (Muller &
Olbrich, 1999). We observed (unpublished data)
that fluorescent SLN are rapidly uptaken from
human U373 tumoral cells (in 5min) and accumu-
late into cytoplasm. Moreover, SLN do not enter
either into the nucleus or into cytoplasmic orga-
nelles such as mitochondria or Golgi apparatus.
Furthermore, after 4h we observed a lysosomal
entrapment of the greater part of the uptaken
nanoparticles. The persistence of few SLN into
the cytoplasm could lead us to suppose the exis-
tence of either alternative concomitant endocytotic
entrance pathways or a mechanism for lysosomal
escape. Moreover, SLN seem to display a biphasic
drug release profile: from 10 to 30min we observed
a characteristic “burst release” phase while from
30min to 24h SLN produced a till robust and
sustained drug delivery. These data seem to suggest
that at early times, corresponding to the cytoplas-
mic localization, SLN rapidly release loaded com-
pounds until an equilibrium with the environment
is reached. Subsequently, the prolonged and till
sustained drug delivery could be probably ascribed
to lysosomal digestion of SLN lipid matrix by resi-
dent acidic lipases (Du, Sheriff, Bezerra, Leonova,
& Grabowski, 1998).
Further studies will clarify both the role played
by different endocytotic processes possibly
involved in SLN tumor cell uptake and the con-
tribute given by the lysosomal escape mechanism
in the delayed drug release phase.
Antineoplastic drugs loaded into SLN
Several chemotherapeutics were incorporated
in SLN, such as doxorubicin, idarubicin, pacli-
taxel, camptothecin, etoposide, SN-38 (irinotecan
analog), retinoic acid, 5-fluorouracil (5-FU),
and TMZ.
Anthracyclin antibiotics such as doxorubicin,
idarubicin, and daunorubicin have general antic-
ancer properties that include interaction with
DNA in a variety of different ways such as inter-
calation, DNA strand breakage, and inhibition
operated by topoisomerase II. Most of these com-
pounds at effective dosages produce significant
toxicity. Doxorubicin (Di Marco, 1978; Stan,
Casares, Radu, Walter, & Brumeanu, 1999) is
currently in clinical use for the treatment of sev-
eral solid tumors, while daunorubicin and idarubi-
cin are exclusively used for the treatment of
leukemia. However, due to their chemical proper-
ties, anthracyclines do not easily pass the BBB and
hence they do not achieve effective intracerebral
concentrations for the treatment of brain tumors.
Moreover, the dose-related characteristic systemic
side effects such as cardiomyopathy, congestive
heart failure (Minotti, Menna, Salvatorelli, Cairo,
& Gianni, 2004; Singal, Li, Kumar, Danelisen, &
Iliskovic, 2000), bone marrow depression, and alo-
pecia (Minow, Benjamin, Lee, & Gottlieb, 1977)
have to be taken into account.
Paclitaxel is a diterpenoid isolated from Taxus
brevifolia that shows anticancer effects against
both hematopoietic and solid tumors (von Holst
et al., 1990). Because of its high hydrophilicity,
paclitaxel does not easily cross the BBB. More-
over, its clinical use is highly limited by systemic
side effects, such as peripheral neuropathy and
cardiac arrhythmia (Rowinsky & Donehower,
1995) as well as alopecia and bone marrow depres-
sion (Minow et al., 1977).
Camptothecin, an alkaloid plant isolated from
Camptotheca acuminata (Wall, Wani, Natschke, &
Nicholas, 1986), is the prototype of antitumor
agents that display a peculiar mechanism of
action. These compounds target the nuclear
enzyme topoisomerase I that physiologically tran-
siently breaks and rejoins DNA strands in order to
facilitate their replication, recombination, and
transcription. Because of poor water solubility,
instability at biological pH, and severe toxicity of
the carboxylated form, camptothecin is not used in
clinical applications (Potmesil, 1994).
Etoposide, a semisynthetic derivative of podo-
phyllotoxin, a substance extracted from the man-
drake root Podophyllum peltatum, shows potent
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antineoplastic properties (Xu, Lv, & Tian, 2009).
More in details, etoposide binds to and inhibits
topoisomerase II main function of ligating cleaved
DNA molecules and consequently induces accu-
mulation of single- or double-strand DNA breaks,
inhibition of DNA replication and transcription,
and apoptotic cell death. Moreover, etoposide do
not readily penetrate the CNS. In the first 24 h
during i.v. administration of etoposide at various
dosages, the concentration of this drug in the CSF
ranges from undetectable to less than 5% of that
concurrently found in the plasma.
SN-38, an irinotecan analog derived from camp-
tothecin (O’Dwyer & Catalano, 2006), is a topoi-
somerase I inhibitor primarily used in the
treatment of colorectal cancer.
Tretinoin, also known as all-trans-retinoic acid,
is a natural derivative of vitamin A. Retinoids are
important regulators of cell reproduction, prolif-
eration, and differentiation and are commonly
used to treat dermatological disorders (Cheepala,
Syed, Trutschl, Cvek, & Clifford, 2007). Further-
more, tretinoin could also be regarded as a pro-
differentiating antineoplastic agent and it is used
in the treatment of acute promyelocytic leukemia
(Cornic et al., 1992).
5-FU — an analog of uracil — is converted to
a fraudulent nucleotide that impair thymidylate
synthesis. The result is inhibition of DNA
synthesis but not RNA or protein production
(Cohen, Flaks, Barner, Loeb, & Lichtenstein,
1958).
TMZ is an orally available methylating agent at
specific DNA sites and thus affects DNA synthesis
and consequently triggers apoptosis. TMZ
became a new standard-of-care treatment of
patients affected by glioblastoma, both as adju-
vant and as concurrent chemotherapy during
radiotherapy (Friedman, Kerby, & Calvert, 2000;
Sathornsumetee et al., 2007). This alkylating agent
is able to pass through the BBB and to achieve
in the CSF approximately 40% of the correspond-
ing plasma concentration. Unfortunately, TMZ
displays adverse effects such as hematological
toxicity and oral ulceration and an unusual
cardiomyopathy, directly due to the accumulation
of the drug in the heart (Sathornsumetee
et al., 2007).
Cytotoxicity of SLN loaded with chemotherapeutic
agents
In vitro, the efficacy of doxorubicin- or paclitaxel-
loaded SLN compared to drug-free solutions were
evaluated in different neoplastic cells, including
glioma and astrocytoma cell lines.
In a recent study our group compared the intra-
cellular accumulation and toxicity in human
tumoral cell lines (including U373 astrocytoma)
of different doxorubicin formulations: loaded
into SLN (Doxo-SLN), carried by pegylated lipo-
somes (Caelyx), and administered as free solu-
tions (Serpe et al., 2006). Doxo-SLN were
significantly more efficient in inhibiting cell
growth in comparison to both pegylated liposomes
and free solutions, suggesting that the intrinsic
characteristics of the delivery system by itself
may improve the uptake and accumulation of dox-
orubicin into the cells.
Doxorucicin- and paclitaxel-SLN showed an
improved cytotoxicity when compared to the free
solutions at same concentrations; moreover, in
human glioma cell lines (U87 and U373) drug-
loaded SLN were able to induce consistent cell
death at lower concentrations (from 10- to 100-
fold) and at shorter exposure times if compared
to drug-free solutions (Mauro & Brioschi, unpub-
lished data, Miglietta et al., 2000).
Recently, polymer–lipid hybrid nanoparticle
and lipid nanoparticles loaded with paclitaxel or
doxorubicin and SLN loaded with vinorelbine
bitartrate were prepared and their cytotoxicity
was tested on tumoral cell lines of nonglial origin,
showing promising results.
Wong and Colleagues developed a new poly-
mer–hybrid nanoparticle system able to load and
release water-soluble doxorubicin; they obtained a
complex between cationic doxorubicin and soy-
bean oil-based anionic polymer, dispersed together
with a lipid in water to form Doxo-loaded SLN
(Wong et al., 2006b). Treatment of Multidrug
Resistant (MDR) cells (human breast cancer)
with this formulation induced an increase of cell
death when compared to the drug-free solution.
Stevens and Colleagues synthesized and incor-
porated paclitaxel-7-carbonyl-cholesterol, a pacli-
taxel prodrug, into lipid nanoparticles that also
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contained folate–PEG–cholesterol as ligand for
targeting folate receptor (FR) expressing tumoral
cells (Stevens et al., 2004). The FR-targeted lipid
nanoparticles showed greater uptake and cyto-
toxicity than the nontargeted ones in FR(þ) cell
lines (M109 and KB) than in FR(–) cell lines
(CHO).
Wan and Colleagues evaluated the uptake and
cytotoxicity of PEG 2000–stearic acid SLN loaded
with vinorelbine bitartrate in RAW26 (mouse
macrophages), MCF-7 (human breast cancer),
and A549 (human alveolar basal epithelial) cell
lines (Wan et al., 2008). They demonstrated that
the phagocytic uptake of SLN by RAW26 are
progressively inhibited by the addition of increas-
ing concentrations PEG 2000; inversely, high
quantities of PEG 2000 promote the intracellular
uptake of SLN by tumoral cell lines such as MCF-
7 and A549, in accordance with previously
reported data (Bocca et al., 1998).
Moreover, the essay of anticancer activity
in vitro demonstrated that, due to the increased
cellular internalization of drug, the cytotoxicity of
vinorelbine bitartrate is enhanced by encapsula-
tion in pegylated SLN.
Jain and Colleagues prepared plain SLN and
SLN loaded with 5-FU subsequently targeted
with ferritin (Fr-SLN) using the ethanol injection
method (S. K. Jain et al., 2008). The cellular
uptake and IC50 values of the Fr-SLN formulation
were determined in vitro in MDA-MB-468 breast
cancer cells. In vitro cell binding of Fr-SLN exhi-
bits 7.7-fold higher binding of Fr-SLN to cancer
cells in comparison to SLN; moreover, cytotoxicity
assays on Fr-SLN gave IC50 of 1.25 mM and
3.56 mM for plain SLN.
In vivo experimental models
SLN pharmacokinetics in healthy animals
Pharmacokinetics of SLN were first studied by us
in healthy rats treated intravenously with Doxo-
SLN or with the free drug solution (Zara et al.,
1999). This study demonstrated the superior effi-
cacy of SLN in achieving and maintaining doxor-
ubicin plasma concentration in comparison to the
free solution. Moreover, SLN were able to modify
the drug biodistribution, in particular, decreasing
heart and liver drug concentration while improv-
ing cerebral accumulation.
Afterward, Fundarò and Colleagues compared
doxo-SLN, stealth doxo-SLN and doxorubicin-
free solution confirming the ability of SLN (stealth
more than nonstealth) to increase plasma half-life
and brain accumulation of doxurubicin (Fundaro
et al., 2000). On the contrary, the free doxorubicin
solution was very rapidly cleared from the blood
stream (in 2.5 h) and is not able to enter the brain
parenchyma. In all rat tissues examined, except
the brain, the amount of doxorubicin was always
lower after injection of the two types of SLN in
comparison to the commercial solution; in parti-
cular, SLN significantly decreased heart concen-
trations, thus decreasing the characteristics side
effects of the drug.
Furthermore, to confirm tissue distribution and
transport across the BBB of modified SLN, both
drug-free and drug-loaded stealth (pegylated) and
nonstealth SLN were administered intravenously
to rats (Podio, Zara, Carazzonet, Cavalli, &
Gasco, 2000a). In the first part of the experiment,
rats were injected with labeled (with 17-[131]iodo-
heptadecanoic acid) nonstealth or stealth SLN and
radioactivity tissue accumulation measured after
60min. This study showed that in liver and lungs
the radioactivity was much lower after stealth-SLN
formulation administration compared to the non-
stealth counterpart, confirming that there is a dif-
ference in body distribution among the two SLN
types, perhaps due to the stealthing agents (stearic
acid and PEG 2000). In the second part of this
work, rats were injected with unlabeled stealth
and nonstealth SLN and after 200 both types of
SLN were detected in the brain thus confirming
the BBB passage, as proved by CSF samples trans-
mission electron microscopy analysis.
Finally, we demonstrated that pegylated dox-
orubicin SLN reach the brain in larger amounts
than the nonstealth SLN and that the brain drug
concentrations increase proportionally to the
percentage of stealth agent used in the formula-
tion (Zara et al., 2002b). Favorable pharmacoki-
netics and tissue distribution were demonstrated
also for idarubicin-loaded SLN after i.v. or
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duodenal administration routes (Zara et al.,
2002a). SLN-based formulation was more effec-
tive in maintaining plasma drug concentrations
than the idarubicin-free solution (improved
AUC). Tissue distribution was significantly mod-
ified by the encapsulation: after SLN administra-
tion, idarubicin and idarubicinol concentrations
are lower in heart, lung, spleen, and kidneys,
while brain accumulation was enhanced. Duode-
nal route further on improved idarubicin phar-
macokinetics compared to i.v. injection, thus
suggesting that SLN can be considered for oral
delivery of antineoplastic drugs in both systemic
and brain tumors.
Yang and Colleagues evaluated the body distri-
bution of intravenously injected camptothecin
SLN (CA-SLN) in C57BL/6J mice (Yang et al.,
1999). SLN were obtained from high-pressure
homogenization technique using camptothecin,
stearic acid, soybean lecithin and Poloxamer 188.
The results of this study showed that the AUC/
dose and the mean residence times of CA-SLN
were much higher than those of camptothecin
solutions, especially in brain, heart, and reticu-
loendothelial cells containing organs.
Chen and Colleagues by using the emulsifica-
tion–evaporation technique, prepared stearic
acid–lecithin SLN containing paclitaxel, coated
with either Brij78 or Poloxamer F68 surfactants
(D. B. Chen, Yang, Lu, & Zhang, 2001). Evalua-
tion of drug pharmacokinetics in Kunming (KM)
mice showed that encapsulation of paclitaxel in
both kind of SLN produce noticeable differences
compared to the free drug (Cremophor EL)
pharmacokinetics.
Huang and Colleagues prepared temozolomide
SLN (TMZ-SLN) by emulsification and low-tem-
perature solidification method (Huang et al.,
2008). The AUC/dose and MRT of the TMZ-
SLN i.v. injected in healthy rabbits demonstrated
much higher and longer than those obtained with
TMZ solution, especially in brain and in reticu-
loendothelial cells-containing organs; moreover
the AUC ratio between the TMZ-SLN and TMZ
solution in the brain was the highest among the
tested organs.
Taken together, these studies demonstrate that
SLN can modify the distribution of loaded drugs.
In particular, doxorubicin, when vehiculated by
SLN, is able to achieve lower concentrations in
lung, liver, and heart compared to the free solu-
tion, thus being able to reduce its systemic toxi-
city. At the same time, doxorubicin brain
accumulation is greatly enhanced if carried by
SLN, allowing cerebral targeting for drug deliv-
ery in brain tumors. Overall, the addition of
stealth agents to SLN seems to improve the
aforementioned properties, mainly by decreasing
the recognition of SLN by the RES in liver and
spleen, thus increasing drug–SLN plasma half-
life.
SLN pharmacokinetics in rats bearing glioma cell
subcutaneous or intracerebral orthotopic
xenografts
In order to assess SLN-mediated drug delivery in
an in vivo glioma model, we established in Wistar
rats orthotopic intracerebral stereotactic C6 cell
implants. At day 14, rats were intravenously
injected with either doxo-SLN or doxorubicin-
free solution. Doxo-SLN achieved intratumoral
drug concentrations ranging from 12- (after
30min) to 50-fold (after 24 h) higher compared
to free solutions at same times. Furthermore, in
the contralateral healthy hemisphere, only doxor-
ubicin vehiculated by SLN was able to reach sub-
therapeutic concentrations, ranging from 3.2 (after
30min) to 12 mg/g (after 24 h), compared to free
drug solution (Mauro & Guido, unpublished
data).
Williams and Colleagues showed that the SLN
formulation of SN-38 is able to increase drug
plasma half-life in nude mice bearing subcuta-
neously xenografted human HT29 cells, a model
of chemoresistant colon adenocarcinoma
(Williams et al., 2003).
Jain and Colleagues in the second in vivo part of
the aforementioned study, treated i.v. nude Balb/c
mice bearing MDA-MB-468 breast cancer cells
subcutaneous xenografts with either 5-FU solu-
tion, plain 5-FU-SLN, or Fr-5-FU-SLN (S. K.
Jain et al., 2008). The authors showed that admin-
istration of Fr-5-FU-SLN formulation results in
effective reduction of tumor growth as compared
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with free 5-FU and plain 5-FU-SLN (delay in
tumor growth and increase in life span). Further-
more, Fr-5-FU-SLN allow an increased drug level
in the tumor and decreased systemic drug accu-
mulation as well as a reduced IC50 compared to
both plain 5-FU-SLN and 5-FU solution.
Further suggestions on how nanoparticles work
in vivo came from three recent studies.
Steininger and Colleagues used an experimen-
tal animal model based on intracerebral
implanted 101/8 glioblastoma cells in rats (Stei-
niger et al., 2004). Implanted rats were injected
at days 2, 5, and 8 with the following formula-
tions: blank PBCA nanoparticles coated with
polysorbate 80 (NPþPS), doxorubicin in saline
(DOX), doxorubicin in 1% polysorbate solution
(DOXþPS), doxorubicin bound to NP (DOX-
NP), or doxorubicin bound to NP coated with
polysorbate (DOX-NPþPS). Rats treated with
DOX-NPþPS showed a significantly higher sur-
vival times compared to all other groups and a
20% rate of long-term remission without any
evidence of neurotoxicity.
Xu and Colleagues produced PEG-coated
PBCA nanoparticles loaded with paclitaxel and
targeted with transferrin (ATN, actively targeta-
ble nanoparticles) or not targeted (NTN, nonac-
tively targeted nanoparticles) (Xu et al., 2005).
Pharmacokinetics and biodistribution studies of
ATN, NTN, and paclitaxel solution were per-
formed in KM strain mice bearing S-180 tumor
nodules of about 10mm, while the evaluation of
antitumor activity in vivo were done in S-180-
bearing KM mice. The authors showed that ATN
exhibited a markedly delay in blood clearance in
mice and higher paclitaxel levels at 24 h after ATN
injection compared to that obtained after free
drug solution administration. The distribution pro-
files of ATN showed that after i.v injection, the
tumor accumulation of paclitaxel increases with
time, and its concentration at 6 h was about 4.8–
2.1 fold higher than those from, respectively, free
paclitaxel and NTN administration. A significant
tumor regression was observed and complete
tumor remission was evident in five out of nine
KM mice treated i.v. with ATN.
Ambruosi and Colleagues investigated the
biodistribution of blank [14C]-PBCA uncoated
and coated with Polysorbate 80 as well as dox-
orubicin-loaded Polysorbate 80-coated [14C]-
PBCA in glioblastoma 101/8-bearing rats after
i.v. injection (Ambruosi et al., 2006). The
authors showed that the overcoating of [14C]-
PBCA-Polysorbate 80 decreased their concen-
trations in RES organs, while the addition of
doxorubicin to the pegylated formulation coun-
teracts the coating effects perhaps by increasing
the positive charge of the particles and conse-
quently by altering their adsorption properties
both to plasma proteins and to other cells in the
body. However, the accumulation of [14C]-
PBCA-Polysorbate 80 nanoparticles in the
tumor site and in contralateral hemisphere of
glioma-bearing rats demonstrated the efficacy
of the enhanced permeability and retention
effect on brain delivery of nanoparticles.
Despite the reduced rate of BBB passage dis-
played by doxorubicin-loaded Plysorbate
80-coated nanoparticles (perhaps due to the
interaction between the drug itself and the sur-
factant), the concentration of doxorubicin at the
tumor site was still higher than in contralateral
hemisphere and in brains from healthy rats.
Taken together, the aforementioned results
clearly showed that nanoparticles, and in particu-
lar SLN, are able to significantly increase intracel-
lular and intratumoral bioavailability of various
chemotherapeutics potentially highly effective for
brain tumors. Furthermore, in comparison to free
solutions, SLN allow a noteworthy reduction in
the amount of incorporated drug required to
produce cytotoxic effects (as showed by the
significant reduction of IC50). In this manner,
drug-related and dose-dependent systemic side
effects could be avoided.
New therapeutical strategies
Prodrugs, solid lipid nanoparticles, and brain
tumors
The use of prodrugs was proposed to overcome
pharmacokinetics limitations of otherwise poten-
tially effective drugs. Till now, the decreased cyto-
toxicity rate, the increased serum opsonization
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(limiting the passage through the BBB), and the
reduced mobility within the brain of the new
synthesized lipophilic analogs compared to the
referring drugs were advocated as the cause of
the disappointing results of prodrugs treatment
of brain tumors (Blakeley, 2008; J. X. Wang,
Sun, & Zhang, 2002).
Wang and Colleagues synthesized from the
cytotoxic agent 5-fluoro-20-deoxyuridine (FUdR)
a lipophilic prodrug, the 30,50-dioctanoyl-5-fluoro-
20-deoxyuridine (DO-FUdR), that in turn was
incorporated into SLN prepared by thin-layer
ultrasonication technique (DO-FUdR-SLN)
(J. X. Wang et al., 2002). A comparative study in
mice showed that DO-FUdR-SLN allow the best
AUC–time curve, MRT and t1/2 value in brain
tissue compared to both DO-FUdR and free
FUdR. More in details, the brain AUC–time
curve of DO-FUdR-SLN was 2.06-fold higher
than that of DO-FUdR and both these curves
were, respectively, 10.97- and 5.32-fold higher
compared to free FUdR. Furthermore, the brain
t1/2 value of DO-FUdR-SLN was 1.49-fold higher
that DO-FUdR. The overall drug targeting effi-
ciency (TEC) of DO-FUdR-SLN to the brain was
about threefold higher compared to free FUdR
solutions (respectively 29.84 and 11.77). More-
over, the TEC of DO-FUdR-SLN was decreased
in the hearth and kidney compared FUdR free
solutions. These data clearly suggest that SLN
are able to further enhance the brain targeting of
even lipophilic prodrugs and perhaps to partially
reduce systemic undesired effects.
Our group chose cholesterylbutyrate (Chol-but)
(Fig. 2) — the ester of cholesterol and butyric
acid — as another matrix to prepare, from warm
oil-in-water microemulsions, Chol-but SLN as a
prodrug of butyric acid (Bach Knudsen, Serena,
Canibe, & Juntunen, 2003, Brioschi, Zara, Calder-
oni, Gasco, & Mauro, 2008). This molecule
belongs to the family of short-chain fatty acids,
physiological compounds produced in the colon
of all mammalian organisms (Bach Knudsen
et al., 2003; Miller, 2004; Santini, Gozzini, Scap-
pini, Grossi, & Rossi Ferrini, 2001), and could be
regarded as a prototype of an effective in vitro
anti-inflammatory and anticancer drug whose
clinical use is heavily limited by its poor
pharmacokinetics (Egorin, Yuan, Sentz, Plai-
sance, & Eiseman, 1999; Miller, 2004; Pouillart,
1998).
Butyrate acts as an anticancer agent by inhibit-
ing proliferation, by stimulating differentiation,
and by inducing apoptosis in a wide panel of neo-
plastic cell lines (including colorectal, breast, gas-
tric, lung, pancreas, and brain districts) (J. S.
Chen, Faller, & Spanjaard, 2003; Miller, 2004;
Santini et al., 2001). Butyrate could be also num-
bered as an endogenous member of the family of
histone deacetylases (HDAC) inhibitors
(HDACI). Disequilibrium in the balance between
histone acetyltransferases and HDAC and altered
expression of HDAC are involved in the develop-
ment and the progression of cancer (Balakin,
Ivanenkov, Kiselyov, & Tkachenko, 2007; Bolden,
Peart, & Johnstone, 2006; J. S. Chen et al., 2003;
J. M. Mehnert & Kelly, 2007). HDACI acts as
antineoplastic agents by increasing acetylation of
both nuclear histones and nonhistone proteins, so
inducing transcriptional and nontranscriptional
effects and consequently gene expression modula-
tion and activation–inhibition of different path-
ways (Balakin et al., 2007; Entin-Meer et al.,
2005; J. M. Mehnert & Kelly, 2007; Minucci &
Pelicci, 2006). HDACI anticancer activities could
also include the regulation of the host immune
responses and tumor angiogenesis (Bhalla, 2005;
Bolden et al., 2006) as well as — in particular for
butyrate — mRNA stabilization and direct action
on gene transcription (Jiang & Sharfstein, 2008;
Lee, Kim, Kummar, Giaccone, & Trepel, 2008;
Miller, 2004). Butyrate displays in vitro a broad
and diversified antineoplastic activity, partially simi-
lar to other HDACI, suggesting a possible use of
this drug as an effective alternative and/or synergic
chemotherapeutic agent. However, in vivo studies
OH3C
H3C
CH3
CH3
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O
Fig. 2. Structure of cholesterylbutyrate.
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on butyrate were disappointing (J. S. Chen et al.,
2003; Conley et al., 1998; Miller, Kurschel, Osieka,
& Schmidt, 1987; Miller, 2004; Patnaik et al., 2002;
Pouillart, 1998; Santini et al., 2001), mainly because
of poor pharmacokinetics (such as rapid plasma
clearance and high liver first pass metabolism) and
adverse events (Miller et al., 1987; Pouillart, 1998;
Patnaik et al., 2002; Santini et al., 2001; Chen, Faller,
& Spanjaard, 2003; Miller, 2004; Conley et al., 1998).
For these reasons, more stable and safer prodrugs of
butyrate, such as acyloxymethyl esters (tributyrin,
AN-1, AN-9), were developed (Entin-Meer et al.,
2007; Nudelman et al., 2001; Reid et al., 2004;
Rephaeli et al., 2006).
Antineoplastic effects of Chol-but SLN were
analyzed in vitro on several cancer cell lines (Pel-
lizzaro et al., 1999; Salomone et al., 2000; Serpe
et al., 2004; Ugazio et al., 2001) and compared to
sodium-butyrate (Na-but).
In nonsmall-cell lung carcinoma cell line (NIH-
H460) cultures Pellizzaro and Colleagues showed
that Chol-but SLN are able to induce 90% cell
growth inhibition at concentration six times lower
than Na-but. Complete growth inhibition was
obtained at a concentration (0.25mM) at which
Na-but causes only about 55% growth reduction
(Pellizzaro et al., 1999; Salomone et al., 2000; Ugazio
et al., 2001).
In melanoma cell lines (human MELTO1 and
mouse B16) Salomone and Colleagues found
that Chol-but SLN compared to Na-but exert
antiproliferative and proapoptotic effects at
lower doses and shorter treatment times.
Furthermore, these effects of Chol-but SLN are
time- and dose-dependent within the first 24 h,
whereas at prolonged times they become strictly
dose-dependent. Moreover, a significant
decrease of proliferating cells and an increase
of cells blocked in the G0/G1 to S transition
phase were seen after 24 h of Chol-but SLN
treatment (Salomone et al., 2000).
In three human leukemic cell lines (Jurkat from
lymphoid, U937, and HL-60 from myeloid origin)
Serpe and Colleagues confirmed that Chol-but
SLN (0.25, 0.5, and 1mM) compared to Na-but
(same concentrations) are able to induce a greater
cell growth inhibition. Furthermore, the authors
showed that c-myc expression is rapidly and
transiently downregulated in all the three cell
lines after Chol-but SLN treatment (0.25mM)
whilst it is slightly decreased only in U937 cells
after Na-but treatment at higher concentrations
(1mM). Cell-cycle arrest caused by Chol-but
SLN is different among the two groups of cells:
block in G1 phase for myeloid (U937 and HL-60)
and mainly in G2 phase for lymphoid cells
(Jurkat). This result could suggest a different
mechanism of action of Chol-but SLN in the var-
ious cell types (Serpe et al., 2004).
Antineoplastic effects of Chol-but SLN were
analyzed in vitro on several cancer cell lines and
compared to Na-but, showing that Chol-but SLN
exert cell growth inhibition and proapoptotic at
lower doses and shorter treatment times in all
the cell lines tested (Figs. 3 and 4). However, in
these studies the effect of Chol-but SLN on the
cell cycle of the various cell lines appeared differ-
ent, suggesting that the mechanisms of the anti-
neoplastic Chol-but SLN effects may be
differently modulated in different cellular contexts
(Serpe et al., 2004).
Moreover, in a pilot study we i.v. treated Wistar
rats bearing intracerebral stereotactic C6 cell
implants with Chol-but SLN 30mg/kg or with sal-
ine every day from day 15th to 21st after implant
and then sacrificed. Morphological and immuno-
histochemical analyses showed a significant
shrinkage in tumors of treated animals. The
implanted area was replaced by large cysts sur-
rounded by residual tumor cells mostly displaying
apoptotic or monstrous (multinucleated) features.
Confocal microscopy studies showed that Fluores-
cent Chol-but SLN, labeled with 6-coumarin were
rapidly internalized into tumor cells and persisted
for few days into their cytoplasms.
In summary, our in vitro studies on different
neoplastic cell lines and preliminary in vivo study
in a rat glioma model convincingly indicate that
Chol-but SLN are able to induce consistent anti-
proliferative and proapoptotic effects earlier and
at significantly lower concentrations compared to
Na-but. The mechanisms of action of Chol-but
SLN and of butyrate are similar but do not com-
pletely overlap. For instance, after Chol-but SLN
treatment, a significant increase in G2/M block
compared to Na-but is observed in some, but not
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in all, of cancer cell lines and the percentage of
apoptotic cells are found higher, even at later
times (unpublished data).
Therefore, Chol-but SLN could be regarded as
suitable and highly effective prodrug of butyric
acid, still maintaining chemical–physical,
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pharmacokinetics, and pharmacodynamic proper-
ties of other SLN formulations.
Chol-but SLN seem to act as other nonselective
HDACI (Peart et al., 2005) by modulating in a
nonspecific manner different pathways, mainly
involved in cell survival and proliferation. In
malignant gliomas, Chol-but SLN, that proved to
modify spontaneous immune response, could act
also as a nonspecific stimulating agent of an
already present but weak host immune reaction
(Carpentier & Meng, 2006).
According to previously reported in vivo data,
Chol-but SLN are able to effectively reach the
CNS and thereby the implanted tumors, and at
the same time to achieve significantly lower con-
centrations in other organs, hence decreasing sys-
temic toxicity.
Antiangiogenetic agents, solid lipid nanoparticles,
and brain tumors
Histological hallmarks of malignant gliomas include
extensive neovascularization. Among CNS neo-
plasms primary malignant gliomas show the highest
new vessel formation rate that is strictly connected
to aggressive clinical behavior (Birner et al., 2003;
R. K. Jain et al., 2007; Johansson, Brannstrom,
Bergenheim, & Henriksson, 2002; Lamszus et al.,
2003; Mischel et al., 2003; Rong, Durden, Van
Meir, & Brat, 2006; Toi, Matsumoto, & Bando,
2001; Zhou, Tan, Hess, & Yung, 2003). Among the
different mechanisms recruiting new blood vessels in
brain tumors, neoangiogenesis is regarded as the
major player because of its direct correlation with
tumor progression and hence with prognosis.
Endothelial proliferations within newly sprouted
vessels (a hallmark of human glioblastomas) is prob-
ably a direct effect of central tumor hypoxia and
necrosis that in turn induce pseudopalisading cells
secreting proangiogenic factors (Rong et al., 2006).
Vascular endothelial growth factor A
(VEGF-A) and its receptor VEGFR2 are consid-
ered crucial players among several known angio-
genic cytokines (Ferrara & Davis-Smyth, 1997;
R. K. Jain et al., 2007; Ke, Shi, Im, Chen, &
Yung, 2000; Ke, Shi, & Yung, 2002; Lamszus
et al., 2003; Rong et al., 2006).
The VEGF family consists of 34- to 45-kDa
dimeric glycosylated protein isoforms.
VEGF165 — the predominant isoform — is pro-
duced in most normal tissues, including the brain,
and in both low- and high-grade gliomas in which
its expression rate directly correlates to grading,
vascularity, clinical behavior, and inversely to
prognosis (Ferrara & Davis-Smyth, 1997; Ferrara,
Gerber, & LeCouter, 2003; Jansen, de Witt
Hamer, Witmer, Troost, & van Noorden, 2004;
Rong et al., 2006; Rosenstein & Krum, 2004a;
Toi et al., 2001).
In brain tumors, VEGF-A expression is mainly
and independently regulated by both hypoxia
(trough the hypoxia-inducible factor-1a, HIF-1a)
and acidosis. In addition, different oncogenes and
tumor suppressor genes, hormones, cytokines, and
signaling molecules are able to modify VEGF
expression pattern (R. K. Jain et al., 2007).
Furthermore, not only malignant cells but also
various host cells (such as stromal cells) and extra-
cellular matrix could express VEGF in response to
toxic insults.
Several experimental attempts to turn off the
HIF/VEGF signaling pathway using different
class of drugs and genes constructs were success-
ful in vitro and in vivo to reduce tumor progres-
sion and angiogenesis. Various compounds such
as angiostatin, anti-VEGF and anti-VEGF recep-
tor (VEGFR) antibodies, inhibitors of VEGFR-2
tyrosine kinase activity, ribozymes, AS-ODN,
and small interfering RNA constructs were
tested to interfere with the VEGF signaling
pathway (Breyer et al., 2000; Farhadi, Capelle,
Erber, Ullrich, & Vajkoczy, 2005; Jansen et al.,
2004; Kim et al., 2005; Lamszus et al., 2003;
Niola et al., 2006; Peoch et al., 2002; Rich &
Bigner, 2004). For instance, several clinical stu-
dies indicated that treatment of recurrent glio-
blastomas patients with a combination of
bevacizumab (anti-VEGF humanized monoclo-
nal antibody), various chemotherapeutics (i.e.,
TMZ, irinotecan) and radiotherapy significantly
increases progression-free survival and reduces
the need for steroids (Norden et al., 2008a; Nor-
den, Drappatz, & Wen 2008b). Till now, different
VEGFR inhibitors are under phase I and II clin-
ical study (Norden et al., 2008a).
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However, these approaches showed significant
limits in the ability of overcome systemic degrada-
tion, reach effective bioavailability in the tumor
target, and avoid systemic toxicity. Common
adverse effects, such as hypertension, proteinuria,
and increased risk of thromboembolism and
hemorrhage, and the evidence that about 50% of
patients develop antiangiogenic therapy resistance
and time-variable response further on limit the
clinical use of these class of therapeutics (Norden
et al., 2008b). These drawbacks could be firstly
related to both the physical–chemical properties
of the drugs and the routes of administration
(Barratt, 2003; Jansen et al., 2004; Koziara et al.,
2006; Muller & Keck, 2004; Pardridge, 2007; Rich
& Bigner, 2004; Tiwari & Amiji, 2006).
Furthermore, recent preclinical studies surpris-
ingly showed that the blocking of VEGF-mediated
neoangiogenesis could promote both tumor infil-
tration (perhaps by overexpression of proinvasive
molecules or by co-option of existing cerebral
blood vessels) and recruitment of circulating
endothelial cells into the neoplasm (Norden
et al., 2008a, 2008b). These data clearly suggest
that at this moment anti-VEGF signaling pathway
inhibition could optimally work only if combined
to other cytotoxic chemotherapeutics, to non-
VEGF-mediated antiangiogenetic factors, or to
radiotherapy (Norden et al., 2008a, 2008b).
We specifically designed — always from warm
oil-in-water microemulsions — SLN vehiculating
VEGF antisense oligonucleotides (VEGF-AS-
ODN SLN) in order to downregulate VEGF
expression in a rat glioma model. We studied the
effectiveness of VEGF-AS-ODN SLN both in vitro
in C6 glioma cell cultures under hypoxic conditions
(Fukumura et al., 2001; Serganova et al., 2004; Tan
et al., 2005), and in vivo in the intracerebral rat C6
glioma model (Brioschi et al., 2009).
In vitro, rat C6 glioma cells under both normal
and hypoxic conditions were treated with VEGF
phosphorothioate AS-ODN, either free or vehicu-
lated by SLN for 24 and 48 h. VEGF phosphor-
othioate sense-ODN (S-ODN) as free solution
and carried by SLN (VEGF-S-ODN SLN) as
well as Fluorescent SLN (Flu-SLN) carrying 6-
coumarin instead of ODN were also tested as
control.
At confocal microscopy observation within
5min after treatment with Flu-SLN a sharp and
homogeneous cytoplasmic green fluorescence
reached the maximum and persisted unchanged
for almost 90min. Western blot analysis of cell
homogenates from untreated normoxic cultures
depicted a pattern of VEGF expression similar to
that found in rat normal heart and brain homo-
genates when compared to that of human controls.
Under hypoxia cotreatment with VEGF-AS-
ODN, VEGF-S-ODN or VEGF-S-ODN SLN did
not produce any appreciable VEGF expression
modulation at both 24 and 48 h. VEGF 120,
VEGF164, and VEGF188 expression at 24 and
48 h increased under hypoxia, as expected, while
progressively decreased after VEGF-AS-ODN
SLN treatment. A statistically significant reduc-
tion (p < 0.01) was evident for all the VEGF iso-
forms after 48 h when compared not only to the
hypoxic but also to the basal conditions (Fig. 5).
In experiments in vivo with the Wistar rat C6
glioma model, the implanted rats were rando-
mized into four main groups, each one treated
for three consecutive days with free VEGF-S-
ODN, free VEGF-AS-ODN, VEGF-S-ODN
SLN or VEGF-AS-ODN SLN, at different con-
centrations. Three days after treatment all the ani-
mals were sacrificed. In control animals, tumor
cells, mainly in the perinecrotic areas and tumor
borders, showed a clear cytoplasmic VEGF immu-
nostaining. Interestingly, a similar VEGF immu-
noreactivity was found in hippocampal neurons as
well as in large pyramidal cortical and cerebellar
Purkinje neurons in both the hemispheres.
In animals treated with VEGF-S-ODN- and
VEGF-AS-ODN-free solutions as well as with
VEGF-S-ODN SLN any appreciable modification
in the VEGF expression in both tumor and normal
brain tissue was found. Only treatment with
VEGF-AS-ODN SLN induced a great reduction
of VEGF expression in both central and peripheral
regions of the tumors. VEGF expression was also
decreased in normal brain tissue, but to a lesser
extent than in tumors (Fig. 6).
In summary, in vitro findings clearly indicate
that our SLN allow highly effective, quick, and
sustained ODN delivery into tumor cells (at least
500-fold more efficient than the free solutions).
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Similar results have been previously described by
Tondelli and Colleagues using c-myb AS-ODN
incorporated in polymeric nanospheres (Saleh,
Stacker, & Wilks, 1996; Tondelli, Ricca, Laus,
Lelli, & Citro, 1998). Taken together these data
demonstrate that SLN could be regarded as a
good carrier not only for chemotherapeutic drugs
but also for gene therapeutical agents. Further-
more, in vivo study showed that VEGF AS-ODN
SLN efficiently downregulate VEGF expression
in neoplastic cells, effectively reaching every part
of the implanted tumors (Brioschi et al., 2009).
Future perspectives and novel challenges
SLN compared to other colloidal carriers display
more versatile structural properties and hence
could be potentially modified in order to vehiculate
simultaneously more than one therapeutical com-
pound. This goal could be reached acting on both
the preparation process and lipid composition as
well as surfactants and cosurfactants use. In this
manner it will be possible to design SLN able to
carry two or more therapeutical agents having dif-
ferent molecular structure and physical–chemical
characteristics. In addition to lipophilic molecules
it could be supposed that more hydrophilic and/or
ionic compounds could be simultaneously loaded
into SLN. Furthermore, SLN may be planned to
allow a different release profile of the carried drugs,
for instance by acting on the preferential location of
the dispersed molecule into the core or into the
shell portion of the nanoparticle. This could lead
to time specific release profile of each carried drug.
These statements suggest a future possible scenario
in which a single carrier could be adapted to differ-
ent requirements. For instance, SLN could be tai-
lored to the clinical course of the disease, and
constructed in order to act as “sensitizer” or pre-
paratory to other therapies (i.e., surgery and radio-
therapy), to take into account the genetic temporal
and spatial heterogeneity of the tumor, and to reci-
procally enhance the effects of the vehiculated
drugs otherwise individually poorly effective.
Targeting to the brain
In the previous part of this chapter we already
showed that SLN could be passively targeted to
the brain by modifying both lipid composition and
production processes. This passive targeting could
be also sustained by the so-called enhanced perme-
ability and retention effect, commonly found in
systemic solid neoplasms (Parveen & Sahoo, 2008;
Wong et al., 2007). The not homogeneous BBB
disruption coupled with the secretion of vascular
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mediators facilitating extravasation and the raised
pressure exerted by tumor mass and surrounding
edema contribute to slow the drainage of macro-
molecules and to facilitate the accumulation within
the tumor of particulate carriers within the tumor
(Parveen & Sahoo, 2008; Wong et al., 2007).
In addition to passive processes, active targeting
is one of the most promising and potentially effec-
tive results of the use of nanoparticulate carriers.
Active targeting could facilitate the SLN transport
into brain tumors but also increase the specificity
of the drug delivery into a peculiar neoplastic cell
population. This could consequently further
reduce the total amount of the drug effectively
needed (and hence the possible systemic toxi-
city) and allow a better selected and temporal
defined antineoplastic effect. Active targeting
implies that SLN surface is suitably designed to
specifically recognize peculiar tissues or cancer
cells. Furthermore, active targeting to brain
tumor cells may facilitate the BBB passage
(Beduneau et al., 2007) addressing different
influx–efflux transport systems displayed
by brain endothelial cells that include
Fig. 6. VEGF immunohistochemistry on xenografted tumor sections from: control rats (a), corresponding negative (without primary
antibody) control rats (b), animals treated with 2mg/kg AS-ODN-free solution (c), and 2mg/kg AS-ODN-SLN (d). VEGF
immunohistochemistry on brain sections (hippocampus) from AS-ODN (e)- and AS-ODN-SLN (f)-treated animals (reproduced
with permission from Brioschi et al., Journal of Nanoneuroscience, 2009).
212
Author's personal copy
carrier-mediated transport (i.e., D-glucose),
receptor-mediated endocytosis [such as insulin,
insulin-like growth factor, folic acid, and trans-
ferrin (Tf)], and adsorptive-mediated endocytosis
(Beduneau et al., 2007; Pardridge, 2007). There-
fore, active targeting of nanoparticulate carriers
to brain tumor cells could be achieved by three
main mechanisms: ligand–receptor interaction,
antibody–antigen recognition, and use of apta-
mers [namely, DNA or RNA fragments that
bind with high affinity and specificity molecular
intracellular and/or membrane-bound targets
(Parveen & Sahoo, 2008)]. All these processes
implies that different classes of targeted com-
pounds are displayed by SLN surface by cova-
lent or notcovalent linkages (Beduneau et al.,
2007).
Ligand–receptor interaction
Tf receptor is 2- to 10-fold overexpressed in most
of the tumor cells compared to normal cells and
hence could be regarded as the prototype of
potential targets useful in order to enhance
carrier–tumor cell interaction. Furthermore, Tf
receptors are also expressed on the luminal mem-
brane of brain endothelial cells and through recep-
tor-mediated endocytosis allow the internalization
of iron-saturated Tf (Fishman, Rubin, Handrahan,
Connor, & Fine, 1987; Gupta, Jain, & Jain, 2007;
Qian, Li, Sun, & Ho, 2002). This result, that seems
to suggest the effectiveness of active BBB crossing,
was disputed because of the demonstration of Tf
retroendocytosis after dissociation from the iron,
the latter compound being the only one comple-
tely transcytosed by endothelial cells (Beduneau
et al., 2007). However, Gupta and Colleagues
developed SLN conjugated with transferrin (Tf-
SLN) and loaded with the antimalarial quinine
dihydrochloride in order to increase the delivery
of these agents to the brain. The authors found
that Tf-SLN show the lowest plasma concentration
and the highest brain uptake compared to noncon-
jugated SLN and free drug solution (Gupta et al.,
2007). FR could be regarded as another possible
useful system to actively target brain tumor cells,
because of its high expression rate at the level of
both endothelial and brain tumor cells (Beduneau
et al., 2007). Stevens and Colleagues showed that
paclitaxel prodrug-loaded SLN conjugated to folic
acid are effective in mice bearing subcutaneously
engrafted murine lung carcinoma cell tumors
(Stevens et al., 2004).
Antibody–antigen recognition
Receptor-specific peptidomimetic monoclonal
antibodies (MAb) could act as “molecular Trojan
horse” and allow BBB crossing by any given
attached compound. Till now, various types of
so-called Trojan horse liposomes proved effective
in brain targeting (Pardridge, 2007).
Tsutsui and Colleagues designed bionanocap-
sules to specifically in vitro and in vivo target
human glioma cells. These nanoparticles, com-
posed of antibody directed against human
EGFR-VIII, were specifically uptaken by human
Gli36 cells in culture and in vivo in a mouse ortho-
topic Gli36 intracerebral glioma model by direct
intratumoral injection (Tsutsui et al., 2007).
Yang and Colleagues showed that a boronated
monoclonal antibody directed against the EGFR-
VIII linked to polyamido amine dendrimers is
effective in a rat glioblastoma model (Yang
et al., 2006b, 2008). This report confirms previous
preclinical studies showing that monoclonal anti-
bodies directed against the extracellular portion of
EGFR-VIII and PDGFR could be effective in the
treatment of gliomas and hence could be used to
specifically target SLN carrying different drugs to
glioma cells (Rich & Bigner, 2004). Similarly anti-
bodies directed toward different target involved in
the glioma VEGF signaling pathway (i.e.,
VEGFR) could be used to target SLN to glioma
endothelial cells possibly interfering with the
angiogenic process (Rich & Bigner, 2004).
Nevertheless, both ligand–receptor and anti-
body–antigen recognition could interact and acti-
vate systemic and local host biological reactions,
potentially interfering with physiological antitu-
moral activities, such as immunological response.
For this reason MAb directed to sites of the
targeted molecule not involved in the endogen-
ous ligand recognition were developed (Beduneau
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et al., 2007). MAb-conjugated liposomes, also
known as immunoliposomes, proved effective as
brain drug delivery systems. For instance, Zhang
and Colleagues developed immunoliposomes, car-
rying a plasmid DNA encoding the EGF receptor
antisense mRNA, conjugated with two MAb direc-
ted to mouse Tf receptor (in order to pass through
the BBB) and to human insulin receptor (in order
to intratumor cell delivery). This study showed
that these immunoliposomes are effective after
i.v. administration in mice bearing U87 brain
tumors (Zhang, Jeong Lee, Boado, & Pardridge,
2002). A similar result was obtained in the same
brain glioma model using immunoliposomes carry-
ing a short hairpin RNA targeting EGFR mRNA
(Boado, 2005; Zhang et al., 2004). Till now, var-
ious colloidal carriers (including pegylated nano-
particles and NLC) conjugated with a murine
MAb antirat Tf (OX26) are under study and
show promising results as brain drug delivery sys-
tems (Beduneau et al., 2007; Pardridge, 2007).
Aptamers
Aptamers (namely, DNA or RNA oligonucleotides
targeted to specific antigens) display some advan-
tages over antibodies such as lower immunogeni-
city, higher target specificity and affinity, and better
tissue penetration. Poly(lactide-co-glycolide)
(PLGA) nanoparticles carrying docetaxel functio-
nalized with an RNA aptamer recognizing a plasma
membrane-specific antigen were successfully tested
in both in vitro and in vivo models of prostate
cancer (Farokhzad et al., 2006a; Farokhzad, Karp,
& Langer, 2006b; Martin-Villalba et al., 2008).
In conclusion, taken together these studies
clearly suggest that SLN — due to their versati-
lity — could be easily and variously engineered in
order to successfully achieve active targeting to
malignant brain tumors.
Gene therapy of brain tumors
Malignant gliomas display high genetic heterogene-
ity, as previously discussed ((62 Martin-Villalba,A.
2008)). In the recent years, many researches
focused on the role of microRNAs (miRNAs)
expression profile in diagnosis, staging, progres-
sion, prognosis, and response to therapy in brain
tumors (Nicoloso & Calin, 2008). The miRNAs
together with short interfering RNA belong to the
family of small regulatory RNAs that act as ribor-
egulators and are the crucial mediators of RNA
interference strategy (Liu, Fortin, & Mourelatos,
2008). The miRNAs — namely, 19–25 nucleotides
in length noncoding RNA — act at posttranscrip-
tional level and are able to regulate gene expres-
sion by reducing the amount of transcribed mRNA
and/or translated proteins (Liu et al., 2008).
Consequently, alterations in miRNAs play a critical
role in tumor initiation, progression, and metastasis
(Liu et al., 2008) and, in fact, glioblastomas display
an miRNAs expression pattern different from nor-
mal brain tissue (Ciafre et al., 2005; le Sage et al.,
2007; Liu et al., 2008). MiR-21 is highly expressed
(from 5- to 100-fold) in human glioblastomas and
seems to act by interfering with the transcription of
critical proapoptotic genes, probably reducing
PTEN protein expression (Chan, Krichevsky, &
Kosik, 2005). Furthermore, the cluster miR-221-
222 is involved in cell-cycle regulation by targeting
the CDK inhibitor p27kip1 (le Sage et al., 2007;
Visone et al., 2007). These findings suggest that
miRNAs could represent potential targets in brain
tumor therapy and different agents such as modi-
fied antisense single-stranded oligonucleotide
complementary to specific miRNA (LNAs anti-
miRNAs) and chemically modified and
cholesterol-conjugated single-stranded RNA com-
plementary to a given miRNA (antagomirs) are
under study in order to achieve targeted miRNA
inhibition (Nicoloso & Calin, 2008). However,
antagomirs showed the same limitations displayed
by other therapeutical compound in order to reach
the CNS bypassing the BBB: these agents were not
able to play any action in the brain when systemi-
cally administered in mice while they proved effec-
tive if directly injected into the mouse cortex
(Krutzfeldt et al., 2007).
We believe that SLN could be suitable carriers
for RNA interference approach as well as, in
broader terms, for gene therapy of brain tumors,
as proved for instance by our work on VEGF AS-
ODN previously reported. Moreover, more
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specific and downstream or upstream located
players belonging to various pathways involved
in glioma initiation and progression, including
neoangiogenesis, could be effectively targeted by
using SLN. Nevertheless, till now active targeting
did not show satisfactory results in clinical trials
and antiangiogenic therapy proved significant
effects only if combined with chemotherapy (San-
son, 2008; Vredenburgh et al., 2007). For instance,
EGFR targeted inhibition in recurrent malignant
gliomas proved dependent by the concomitant
switching-off of the downstream PI3K/AkT path-
way (Mellinghoff et al., 2005). However, clinical
trials addressing both EGFR and PI3K/AkT (so
called “vertical targeting”) showed disappointing
results, probably because of the concurrent activa-
tion of multiple tyrosine kinase pathways (Sanson,
2008). Therefore, the concomitant targeting
(“horizontal targeting”) of more than one tyrosine
kinase receptors activated in malignant gliomas
could be effective (Sanson, 2008; Stommel et al.,
2007). Once more, SLN could offer a resourceful
colloidal carrier platform for both vertical and
horizontal targeted therapies of malignant
gliomas.
Brain tumors imaging and thermotherapy
Till now, several types of nanoparticles targeted
mainly to vascular epitopes (such as magnetic
particles, quantum dots, immunotargeted nano-
shells, liposomes, and dendrimers) have been
developed for systemic cancer detection in order
to increase both intratumor retention times and
contrast enhancement. The use of these nanopar-
ticles could allow not only earlier detection and
prolonged observation times of the neoplastic
lesions but also— according to the targeting mole-
cules employed — more detailed phenotypical
and/or genetic characterization of detected tumors
(Parveen & Sahoo, 2008).
Superparamagnetic nanoparticles were devel-
oped as MRI contrast agents in order to increase
the selectivity and detection abilities of brain
tumor imaging (Chertok, David, Huang, & Yang,
2007; Muldoon, Sandor, Pinkston, & Neuwelt,
2005; Reddy et al., 2006). Different magnetic
nanoparticles composed of a magnetic core
(usually iron oxide) produce aMRI visible hypoin-
tense signal drop out on T2-weighted images
(negative contrast) due to their ability to strongly
enhance proton spin–spin relaxation (Y. X. Wang,
Hussain, & Krestin, 2001). Polyacrylamide nano-
particles encapsulating iron oxide proved excellent
tumor contrast enhancement after i.v. administra-
tion to rats bearing intracranial 9L gliomas
(Moffat et al., 2003; Reddy et al., 2006).
Our group studied the pharmacokinetics and
biodistribution of SLN loaded with superparamag-
netic iron oxides (SLN-FeA and SLN-FeB) com-
pared to Endorem as contrast agents for MRI in
rats. After parenteral administration both types of
SLN-Fe showed a slower blood clearance and a
more prolonged CNS retention time (up to 1350)
compared to the commercial MRI contrast agent
Endorem (Peira et al., 2003).
Thermal ablation (namely, thermotherapy) often
combined to chemotherapy could be potentially
effective in the treatment of malignant gliomas
but is highly limited by its nonfocalized field of
action (Jain, 2007). Recent studies proved that
both in animal glioma models and in selected
patients (Maier-Hauff et al., 2007) the injection of
magnetic nanoparticles into the tumors followed by
exposure to an alternating magnetic field allows to
a prolongation of survival, induces regression of
tumor growth and is well tolerated. Moreover, sev-
eral studies showed that magnetic nanoparticles,
due to their magnetic responsiveness, could be
retained at tumor sites for longer times after local
application of external magnetic field (Chertok
et al., 2007). Chertok and Colleagues recently
demonstrated that — in rats bearing intracerebral
orthotopic 9L-gliosarcoma tumors — the concomi-
tant application of brain targeting magnetic field
during i.v. administration of iron oxide nanoparti-
cles induces a fivefold increase in tumor exposure
to these nanoparticles compared to nontargeted
neoplasms and a 3.6-fold rise in selective nanopar-
ticles accumulation in tumors than in normal brain
tissue (Chertok et al., 2007).
Taken together these data suggest that SLN —
either specifically coated with glioma tumor-targeting
agents or brain targeted usingmagnetic field exposure
— could work as innovative tools in the field of brain
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tumors imaging by improving sensibility and speci-
ficity of commonly used techniques. Moreover, the
feasibility of loading these tumor-targeted imaging-
devoted SLN with different classes of antineoplastic
agents could argue their possible use as neuroima-
ging and concomitantly therapeutic carriers, opening
the way of a selective, localized, and concomitant or
subsequent thermo- and chemotherapy.
Thereby the prolonged retention time allows
long-lasting observation time of the tumor beha-
vior and hence could be useful in noninvasive
in vivo MRI monitoring of therapeutical effects
produced by SLN-carried drugs.
Future SLN therapeutical applications
Furthermore, SLN could be used to enhance the
effects of new attractive targeted therapeutical
strategies of brain tumors, such as boron neutron
capture therapy (BNCT) and photodynamic ther-
apy (Jain, 2007).
– BNCT could allow highly localized radiotherapy,
possibly limited to a range of a single neoplastic
cell, by producing a nuclear reaction between
thermal neutrons and 10B, leading to generation
of a particles and 7Li nuclei (Jain, 2007). As
previously reported, boronated antibodies
directed against to specific glioma targets could
be effective if conjugated to different carriers
(Yang et al., 2006a). Thereby, it will be possible
to design SLN carrying on their surface glioma
targeted boronated antibodies and this
could open the way to highly localized
cotreatments. For instance, by including into
these SLN different antineoplastic agents
(i.e., radiosensitizers, chemotherapeutics, gene
constructs) we could obtain concomitant or
subsequent potentiation of localized radiotherapy.
– The use of a photosensitizer (such as
Photofrin) for photodynamic therapy is based
on the ability of this class of compounds to
generate, after exposure to a specific wavelength
light, toxic oxygen species into target cells. This
therapy is greatly limited by systemic (and in
particular cutaneous) side effects (Jain, 2007;
Parveen & Sahoo, 2008). Reddy and Colleagues
incorporated into a polymeric nanoparticle
targeted to tumoral neovasculature both
Photofrin and iron oxide, showing that,
compared PDT delivered after treatment with
either Photofrin or nontargeted nanoparticles
alone, these nanoparticles were more effective in
prolonging survival in a rat intracerebral glioma
model after Photodynamic Therapy (PDT)
(Reddy et al., 2006). Better MRI resolution
obtained by the use of these targeted
nanoparticles vehiculating iron oxide could
contribute to improve intracranial localization of
the tumor and hence to facilitate PDT
administration. Further on, superparamagnetic
SLN could be successfully used for PDT if
adequately coated with glioma tumor-targeting
agent and loaded also with a photosensitizer
molecule.
Conclusions
In the previous sections of this chapter we showed
that SLN — due to their versatile properties —
could be regarded as efficacious colloidal carriers
for different classes of agents useful in both ima-
ging and treatment of malignant gliomas. SLN
allow the effective employment of otherwise
toxic (and hence poorly efficacious at safer
dosages) chemotherapeutics and could effica-
ciously vehiculate molecules having different che-
mical and ionic structure, including gene
constructs, and acting on distinct pathways
involved in tumor initiation–progression. Further-
more, these nanoparticles could be designed to
escape the RES and thereby to passively target
the brain, so increasing the AUC curve rate and
prolonging the exposition time. Moreover, active
targeting as well as the possibility of simulta-
neously vehiculate more than one compound and
the feasibility of different release profiles are
more than an attractive realistic perspective.
These latter SLN properties could further on con-
tribute to increase the drug selectivity contempor-
aneously reducing systemic toxicity. In summary,
SLN could work as a highly flexible platform for
brain tumor imaging and therapeutical purposes,
allowing a more tailored approach to both
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genetically–phenotypically distinct malignant glio-
mas and patients’ stratification.
Nevertheless, our data clearly showed that even
the most passively brain targeted SLN at the low-
est effective concentration used reach every part
of the body where they could release the vehicu-
lated drug. Furthermore, once crossed the BBB,
nonactively targeted SLN carry the therapeutical
agent in every CNS region where, on the contrary,
it could be undesirable and/or dangerous. As pre-
viously described, VEGF-AS-ODN SLN can
reduce VEGF expression not only in glioma cells
but also in hippocampal neurons, potentially inter-
fering with protective and repair processes invol-
ving VEGF (Krum & Rosenstein, 1998;
Rosenstein & Krum, 2004b; Yano et al., 2005;
Yasuhara et al., 2005).
This intra-CNS low selectivity claims on the one
hand further in vivo studies directed to identify
the minimal effective drug dose needed and on the
other hand the development of more selective
active-targeted SLN, in order to minimize unde-
sired effects in normal brain but also in healthy
systemic tissues.
Despite these latter suggested possible limitations
anyway it would be advisable to plan well designed
and controlled phase I and phase II clinical trials in
humans with SLN carrying antiglioma drugs.
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